These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3888046)

  • 1. Hormone stimulation and chemotherapy in advanced prostate cancer: preliminary results of a prospective controlled clinical trial.
    Manni A; Santen RJ; Boucher A; Lipton A; Harvey H; Simmonds M; White D; Gordon R; Ronher T; Drago J
    Anticancer Res; 1985; 5(2):161-5. PubMed ID: 3888046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trial.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon RA; Rohner T; Drago J
    Anticancer Res; 1986; 6(2):309-14. PubMed ID: 3518596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen priming and response to chemotherapy in advanced prostatic cancer.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon RA; Rohner TJ; Drago J
    J Urol; 1986 Dec; 136(6):1242-6. PubMed ID: 3534315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome.
    Manni A; Bartholomew M; Caplan R; Boucher A; Santen R; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon R
    J Clin Oncol; 1988 Sep; 6(9):1456-66. PubMed ID: 3047336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; Gordon R; Rohner T; Drago J; Wettlaufer J
    J Steroid Biochem; 1987; 27(1-3):551-6. PubMed ID: 3695494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone.
    Bezwoda WR
    Br J Urol; 1990 Aug; 66(2):196-201. PubMed ID: 2143960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer.
    Gennatas CS; Kalovidouris A; Paraskevas GA; Kouvaris J; Trichopoulos D; Papavasiliou C
    Radiother Oncol; 1987 Jul; 9(3):217-20. PubMed ID: 3628857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of aminoglutethimide +/- estrogen before chemotherapy in advanced breast cancer.
    Lipton A; Santen RJ; Harvey HA; Manni A; Simmonds MA; White-Hershey D; Bartholomew MJ; Walker BK; Dixon RH; Valdevia DE
    Am J Clin Oncol; 1987 Feb; 10(1):65-70. PubMed ID: 3548314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of CEA and GCDFP-15 plasma level during hormonally induced cancer stimulation.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Drago J; Rohner T; Haagensen D; Glode M; Santner SJ
    Anticancer Res; 1984; 4(3):141-4. PubMed ID: 6380398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy.
    Labrie F; Dupont A; Bélanger A; Cusan L; Brochu M; Turina E; Pinault S; Lacourciere Y; Emond J
    Br J Urol; 1989 Jun; 63(6):634-8. PubMed ID: 2752257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
    Kruit WH; Stoter G; Klijn JG
    Anticancer Drugs; 2004 Oct; 15(9):843-7. PubMed ID: 15457124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
    Sartor O; Cooper M; Weinberger M; Headlee D; Thibault A; Tompkins A; Steinberg S; Figg WD; Linehan WM; Myers CE
    J Natl Cancer Inst; 1994 Feb; 86(3):222-7. PubMed ID: 7506794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
    Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
    Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of aminoglutethimide on steroid synthesis of the adrenal gland and its use in prostate cancer].
    Knönagel H; Hauri D
    Helv Chir Acta; 1989 Aug; 56(3):347-50. PubMed ID: 2807964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical studies with aminoglutethimide in advanced breast carcinoma.
    Harvey HA; Lipton A; Santen RJ
    Acta Clin Belg Suppl; 1986; 11():29-40. PubMed ID: 3459321
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
    Taneja SS
    J Urol; 2014 Mar; 191(3):656. PubMed ID: 24522033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.